KDNY
Chinook Therapeutics, Inc.
Set alert
40.39 0.00 0.00%
40.30 Day range 40.51
52-week range unavailable
- Open
- 40.31
- Prev close
- 40.39
- Mkt cap
- 2.63B
- Vol
- 3.28M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 40.30
- High
- 40.51
- Forward P/E
- -11.37
- Beta
- 0.68
- Short ratio
- 1.24
- Inst. own
- 96.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2023
- 50-d avg
- 29.15
- 200-d avg
- 24.27
- 1y target
- 39.30
Financial health
Altman Z-Score
9.74 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -9.1×
FY 2015 5y median -7.3× FY 2022
P/S 275×
FY 2015 5y median 253× FY 2022
P/B 3.8×
FY 2015 5y median 1.6× FY 2022
P/FCF -14.2×
FY 2015 5y median -14.2× FY 2022
EV/EBITDA -9.6×
FY 2015 5y median -9.6× FY 2022
EV/Sales 263×
FY 2015 5y median 76.0× FY 2022
FCF Yield -7.1%
FY 2015 5y median -7.1% FY 2022
Profitability
Gross Margin 71.9%
FY 2015 5y median 96.1% FY 2022
Operating Margin -3020.3%
FY 2015 5y median -671.8% FY 2022
Net Margin -3012.6%
FY 2015 5y median -632.0% FY 2022
ROE -41.8%
FY 2015 5y median -24.4% FY 2022
ROIC -35.0%
FY 2015 5y median -30.7% FY 2022
ROA -32.2%
FY 2015 5y median -26.7% FY 2022
Growth (YoY)
Revenue -88.1%
FY 2015 FY 2022
Operating Income -86.9%
FY 2015 FY 2022
EPS (diluted) -29.3%
FY 2015 FY 2022
Free Cash Flow -13.9%
FY 2015 FY 2022
Financial Health
Current Ratio 7.6×
FY 2015 5y median 7.6× FY 2022
Quick Ratio 7.6×
FY 2015 5y median 7.6× FY 2022
Debt / Equity 0.1×
FY 2015 5y median 0.1× FY 2022
Net Debt / EBITDA 0.5×
FY 2015 5y median 1.2× FY 2022
Interest Coverage -25.8×
FY 2015 5y median -25.8× FY 2022
Dividends
Dividend Yield 0.0%
FY 2015 5y median 0.0% FY 2022
Payout Ratio 0.0%
FY 2015 5y median 0.0% FY 2022
Annual · latest fiscal year ends 2022-12-31